Show simple item record

dc.contributor.authorMelamed, E
dc.contributor.authorLevy, M
dc.contributor.authorWaters, PJ
dc.contributor.authorSato, DK
dc.contributor.authorBennett, JL
dc.contributor.authorJohn, GR
dc.contributor.authorHooper, DC
dc.contributor.authorSaiz, A
dc.contributor.authorBar-Or, A
dc.contributor.authorKim, HJ
dc.contributor.authorPandit, L
dc.contributor.authorLeite, MI
dc.contributor.authorAsgari, N
dc.contributor.authorBroadley, SA
dc.contributor.authoret al.
dc.date.accessioned2021-06-30T01:42:28Z
dc.date.available2021-06-30T01:42:28Z
dc.date.issued2015
dc.identifier.issn2332-7812en_US
dc.identifier.doi10.1212/NXI.0000000000000134en_US
dc.identifier.urihttp://hdl.handle.net/10072/405469
dc.description.abstractNeuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.en_US
dc.languageenen_US
dc.publisherOvid Technologies (Wolters Kluwer Health)en_US
dc.relation.ispartofpagefrome134en_US
dc.relation.ispartofissue4en_US
dc.relation.ispartofjournalNeurology: Neuroimmunology and NeuroInflammationen_US
dc.relation.ispartofvolume2en_US
dc.titleUpdate on biomarkers in neuromyelitis opticaen_US
dc.typeJournal articleen_US
dcterms.bibliographicCitationMelamed, E; Levy, M; Waters, PJ; Sato, DK; Bennett, JL; John, GR; Hooper, DC; Saiz, A; Bar-Or, A; Kim, HJ; Pandit, L; Leite, MI; Asgari, N; Broadley, SA; et al., Update on biomarkers in neuromyelitis optica, Neurology: Neuroimmunology and NeuroInflammation, 2015, 2 (4), pp. e134-e134en_US
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.date.updated2021-06-30T00:03:42Z
dc.description.versionVersion of Record (VoR)en_US
gro.rights.copyright© 2015 American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commerciallyen_US
gro.hasfulltextFull Text
gro.griffith.authorBroadley, Simon


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record